DermEffects: Dr. Wei Jing Loo
1560 Hyde Park Road
London, ON N6H 5L5
(519) 472-8686 (Cosmetic Inquiries)
(519) 472-2929 (Medical Inquiries)
(519) 472-8484 (Fax)
Monday–Friday: 7 a.m.–3 p.m.

Research & Clinical Trials

Dr. Loo is an adjunct professor at the University of Western Ontario and is very familiar with the rigor needed to conduct research and clinical trials that produce valuable results.

Dr. Wei Jing Loo uses her expertise and extensive training to help advance the fields of medical and cosmetic dermatology through her London, Ontario, practice. Regulatory agencies such as Health Canada and the FDA in the United States require clinical research trials before approving new treatments, preventive procedures, or devices.

Dr. Loo is an adjunct professor at the University of Western Ontario and is very familiar with the rigor needed to conduct research and clinical trials that produce valuable results. She has published her work in many peer-reviewed journals and has presented her research at national and international meetings.

Dr. Loo is an adjunct professor at the University of Western Ontario and is very familiar with the rigor needed to conduct research and clinical trials that produce valuable results.

Dr. Loo and her staff follow strict protocols and regulations when conducting clinical research trials.

Patients interested in participating in a clinical trial, sometimes called clinical studies, can volunteer by contacting DermEffects. If you’re accepted to participate, you can also decide to withdraw at any time.

Other important information to know for patients who participate in clinical research trials include:

  • Your participation is voluntary.
  • All information about you remains confidential.
  • Before participating in a study, Dr. Loo or another member of the clinical research team will explain all the details about the study to patients, including any potential risks or benefits, and answer all questions.
  • Patients have as much time as necessary to decide if they want to participate.
  • Patients who decide to participate must sign a consent form. They will keep a copy of this consent form, which contains additional information about the clinical research trial.

An Elite Skincare Specialist

Dr. Loo is an experienced, board-certified dermatologist who established DermEffects with a vision of providing excellent cosmetic and medical skin care.

Meet Dr. Wei Jing Loo Request a Consultation

Every clinical research trial is submitted to an independent research ethics board for approval before the study can be performed.

If you’re interested in learning about current clinical research trials, please visit ResearchTrials.org.

Please note that a physician referral is required for all medical consultations and treatments. Medical consultations are a benefit of Ontario Health Insurance Plan (OHIP). Elective services offered at DermEffects are not covered by OHIP.

Active Clinical Trials

We are currently recruiting for the following studies:

Atopic Dermatitis (Eczema) – 65 weeks

The purpose of this study is to assess the safety and effectiveness of an investigational injection medication (active study drug) compared to placebo (inactive substance) in the treatment of moderate-to-severe eczema.

Men and women who have had a diagnosis of atopic dermatitis for at least 2 years and are aged 12 and older may qualify to receive study drug at no cost. There is no cost to participate, and participants will receive compensation for travel related expenses.

In order to qualify, participants must have at least 10% of their body surface area covered in eczema, excluding their palms, soles, and scalp. This is equivalent to 10 palm sized patches, including fingers.

Participants will be asked to visit the study centre about 11 times and participate in one phone call visit over a period of about 65 weeks.

Email Tina Craig, Clinical Research Coordinator at DermEffects to register.

Atopic Dermatitis (Eczema) – 36 weeks

Adults 18-75 years of age with symptoms, or a diagnosis, of atopic dermatitis for at least 3 years may qualify to participate. Individuals must have atopic dermatitis covering 10% or more of their body, with moderate to severe disease at the time of study entry. Participants must also have no prior exposure to biologic medication.

Eligible participants will receive the investigational medication (active drug), dupilumab (a monoclonal antibody used for allergic diseases), or a placebo (inactive substance). These substances will be administered orally and by injection. Study medication and study-related care will be provided at no cost. Reimbursement for study-related expenses may be provided, along with an optional open label extension upon completion of the trial.

Study participation will last about 36 weeks and include about 16 visits to the study centre.

Email Tina Craig, Clinical Research Coordinator at DermEffects to register.

Hidradentitis Suppurativa – 26 weeks

Men and women aged 18-75 years old with a diagnosis of hidradenitis suppurativa (HS) and disease lasting for at least 1 year, may qualify to participate in this study. Individuals must have moderate to severe hidradenitis suppurativa with 4 lesions or more in at least 2 distinct areas.

Participants must first commit to a 4-week trial of oral antibiotics in which the medication yields an inadequate response. Eligible participants will receive investigational oral medication (active drug or placebo). Study medication and study-related care will be provided at no cost. Reimbursement for study-related expenses may be provided.

Study participation will last up to 26 weeks and include about 10 visits to the study centre.

Email Tina Craig, Clinical Research Coordinator at DermEffects to register.

Chronic Spontaneous Uritcaria (Hives) – 16 weeks

Men and women ages 18 years or older with chronic spontaneous uritcaria may qualify to participate. Hives must be present on the individual for at least 6 weeks prior to the start of the study, with a diagnosis of the disease for at least 6 months prior. A history (within 6 months) of inadequate response to treatment with anti-histamines, is also required.

Participants will receive investigational oral medication (active study drug) or placebo during the treatment period. Study medication and study-related care will be provided at no cost. Reimbursement for study-related expenses may be provided.

Study participation will last about 16 weeks and involve about 7 visits to the study centre.

Email Tina Craig, Clinical Research Coordinator at DermEffects to register.

Scalp and Body Psoriasis – 8 weeks

The purpose of this study is to assess the safety, effectiveness and tolerability of an investigational cream compared to placebo (inactive substance) over 8 weeks in individuals with scalp and body psoriasis involving at least 10% of scalp and less than 25% of total body.

Men and women aged 12 and older with mild to moderate scalp and body psoriasis may qualify to receive study drug at no cost. There is no cost to participate, and participants will receive compensation for study-related expenses.

Study participation will last 8 weeks and involve 6 visits to the study centre.

Email Tina Craig, Clinical Research Coordinator at DermEffects to register.

Plaque Psoriasis – 8 weeks

Individuals 12 years of age or older with a diagnosis of plaque psoriasis for at least 6 months, may qualify to participate. Eligible participants must have plaque psoriasis covering 2-20% of their body, not including scalp, palms or soles of the feet, with mild to moderate disease at the time of study entry.

Participants will receive investigational topical medication (active drug) or a placebo. Study medication and study-related care will be provided at no cost. Reimbursement for study-related expenses may be provided, along with an optional open label extension upon completion of the trial.

Study participation will last 8 weeks.

Email Tina Craig, Clinical Research Coordinator at DermEffects to register.

Upcoming Studies: Hidradentitis Suppurativa – 71 weeks

Men and women ages 18 years or older with a diagnosis of hidradenitis suppurativa (HS) and disease lasting for at least 6 months, may qualify to participate in this study. Individuals must have moderate to severe hidradenitis suppurativa with 5 or more inflammatory lesions in at least 2 distinct areas. Must also have no prior use of Cosentyx, Siliq or Taltz, and an inadequate response to oral antibiotics.

Eligible participants will receive investigational injection medication (active drug or placebo). Study medication and study-related care will be provided at no cost. Reimbursement for study-related expenses may be provided.

Study participation will last up to 71 weeks and include about 29 visits to the study centre.

Email Tina Craig, Clinical Research Coordinator at DermEffects to register.

Observational Psoriasis Research Study

You may qualify if you take pills, injections, infusions, or are receiving light therapy for psoriasis. Participants must be 18 or older. If you qualify, you’ll have regular visits with psoriasis specialists. There is no cost to participate, and participants will receive reasonable compensation for travel or parking cost.

Participants will be asked to visit the study centre about 11 times over a 5 year period.

Email Tina Craig, Clincal Research Coordinator at DermEffects to register.